Factor Eight Inhibitor Bypassing Activity

[1]  P. Cortesi,et al.  Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. , 2011, The New England journal of medicine.

[2]  J. Modrof,et al.  Inactivation of parvovirus B19 during STIM‐4 vapor heat treatment of three coagulation factor concentrates , 2008, Transfusion.

[3]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[4]  J. G. van der Bom,et al.  Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. , 2007, Blood.

[5]  L. Valentino,et al.  Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[7]  L. Valentino.  FEIBA prophylaxis for patients with haemophilia and inhibitors , 2006 .

[8]  J. Oldenburg,et al.  Genetic risk factors for inhibitors to factors VIII and IX , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  C. Négrier,et al.  A retrospective postlicensure survey of FEIBA efficacy and safety , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  P. Mannucci,et al.  Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study , 2005, British journal of haematology.

[11]  B. Jude,et al.  Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor , 1992, Annals of Hematology.

[12]  E. Duncan,et al.  Low detection rate of antibodies to non‐functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  J. Astermark,et al.  Monitoring the bioavailability of FEIBA with a thrombin generation assay , 2003, Journal of thrombosis and haemostasis : JTH.

[14]  K. Mann,et al.  What is all that thrombin for? , 2003, Journal of thrombosis and haemostasis : JTH.

[15]  A. Ward,et al.  Factor Xa is highly protected from antithrombin–fondaparinux and antithrombin–enoxaparin when incorporated into the prothrombinase complex , 2003, Journal of thrombosis and haemostasis : JTH.

[16]  J. Astermark,et al.  Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay , 2003, Pathophysiology of Haemostasis and Thrombosis.

[17]  A. Mäkipernaa,et al.  Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  G. Kenet,et al.  A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®) , 2003, Journal of thrombosis and haemostasis : JTH.

[19]  J. Macleod,et al.  Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. , 2002, The Journal of trauma.

[20]  F. Dorner,et al.  A Fully Recombinant Partial Prothrombin Complex Effectively Bypasses fVIII In Vitro and In Vivo , 2002, Thrombosis and Haemostasis.

[21]  F. Dorner,et al.  Activation and inactivation of human factor X by proteases derived from Ficus carica , 2002, British journal of haematology.

[22]  W. Muntean,et al.  Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  J. Oldenburg,et al.  Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. , 2002, Seminars in thrombosis and hemostasis.

[24]  H. Ehrlich,et al.  Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  A. Shapiro.  Inhibitor treatment: state of the art. , 2001, Seminars in hematology.

[26]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[27]  P. Walsh,et al.  Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. , 2000, Biochemistry.

[28]  H. Schwarz,et al.  Factor Xa and Prothrombin: Mechanism of Action of FEIBA , 1999, Vox Sanguinis.

[29]  Scharrer,et al.  Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  Leissinger.  Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  K. Mann,et al.  Measurement of Active Coagulation Factors in Autoplex®-T with Colorimetric Active Site-Specific Assay Technology , 1998, Thrombosis and Haemostasis.

[32]  P. Uberfuhr,et al.  Thromboembolic Complications Associated with the Use of Prothrombin Complex and Factor IX Concentrates , 1998, Thrombosis and Haemostasis.

[33]  R. Bagnall,et al.  Factor VIII inhibitors in mild and moderate‐severity haemophilia A , 1998, Thrombosis and haemostasis.

[34]  P. Walsh,et al.  Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. , 1998, Biochemistry.

[35]  H. Ehrlich,et al.  Comparison of High Responder Inhibitor Frequency in Recent Studies of Previously Untreated Patients with Hemophilia A , 1998, Thrombosis and Haemostasis.

[36]  A. Girolami,et al.  Prevalence of anti‐FVIII antibodies in severe haemophilia A patients with inversion of intron 22 , 1997, British journal of haematology.

[37]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[38]  H. Schwarz,et al.  Assessment of Bleeding for the Evaluation of Therapeutic Preparations in Small Animal Models of Antibody-Induced Hemophilia and von Willebrand Disease , 1997, Thrombosis and Haemostasis.

[39]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[40]  A. Girolami,et al.  High incidence of anti‐FVIII antibodies against non‐coagulant epitopes in haemophilia A patients: a possible role for the half‐life of transfused FVIII , 1996, British journal of haematology.

[41]  S. Nomura,et al.  The effect of non-activated prothrombin complex concentrate (Proplex ST) on intraperitoneal hematoma in a hemophilia A patient with a factor VIII inhibitor. , 1996, Internal medicine.

[42]  C. Escuriola-Ettingshausen,et al.  Epidemiology of Inhibitors in Haemophilia A , 1996, Vox sanguinis.

[43]  H. Hemker,et al.  Prothrombin Contributes to the Assembly of the Factor Va-Factor Xa Complex at Phosphatidylserine-containing Phospholipid Membranes (*) , 1995, The Journal of Biological Chemistry.

[44]  P. Giangrande,et al.  A cross‐over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate , 1994, British journal of haematology.

[45]  H. Ronneberger,et al.  Activity of coagulation and fibrinolysis parameters in animals. , 1994, Arzneimittel-Forschung.

[46]  R F Doolittle,et al.  The Evolution of Vertebrate Blood Coagulation: A Case of Yin and Yang , 1993, Thrombosis and Haemostasis.

[47]  K. Hampton,et al.  Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate , 1993, British journal of haematology.

[48]  Y. Sultan,et al.  In vitro evaluation of factor VIII--bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets. , 1993, The Journal of laboratory and clinical medicine.

[49]  Macik Bg.  Treatment of Factor VIII Inhibitors: Products and Strategies , 1993, Seminars in thrombosis and hemostasis.

[50]  I. Macgregor,et al.  A Novel Rat Model of Thrombogenicity: Its Use in Evaluation of Prothrombin Complex Concentrates and High Purity Factor IX Concentrates , 1992, Thrombosis and Haemostasis.

[51]  P. Comfurius,et al.  Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. , 1992, Biochimica et biophysica acta.

[52]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[53]  P. Mannucci,et al.  No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate , 1991, British journal of haematology.

[54]  C. Prowse,et al.  Comparison of High Purity Factor IX Concentrates and a Prothrombin Complex Concentrate in a Canine Model of Thrombogenicity , 1991, Thrombosis and Haemostasis.

[55]  P. Mannucci,et al.  Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. , 1990, Blood.

[56]  G. Harbauer,et al.  Comparison of different prothrombin complex concentrates--in vitro and in vivo studies. , 1990, Thrombosis research.

[57]  M. Hilgartner,et al.  Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study Group , 1990, Transfusion.

[58]  A. Giles,et al.  The Role of Factor VII in Haemostasis: Infusion Studies of Factor VIIa in a Canine Model of Factor VIII Deficiency , 1990, Thrombosis and Haemostasis.

[59]  L. Patthy.  Evolution of blood coagulation and fibrinolysis. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[60]  Y. Sultan,et al.  Treatment of factor VIII inhibitors. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[61]  W. Kisiel,et al.  Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. , 1989, Blood.

[62]  M. Read,et al.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Freedman,et al.  The Endothelial Cell and the Factor VIII Bypassing Activity of Prothrombin Complex Concentrate , 1988, Thrombosis and Haemostasis.

[64]  K. Mann,et al.  A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo , 1988, British journal of haematology.

[65]  A. Giles,et al.  In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). , 1988, Blood.

[66]  H. Kingdon,et al.  PROPLEX vs. PROPLEX SX: a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII. , 1986, Thrombosis research.

[67]  G. Tishkoff,et al.  Apparent intrinsic prothrombinase activity of human Factor X zymogen: identification with Factor VIII inhibitor bypassing activity (FEIBA). , 1984, Thrombosis research.

[68]  W. Muntean.  Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma. , 1984, Wiener Klinische Wochenschrift.

[69]  A. Giles,et al.  Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency) , 1984 .

[70]  P. Levine,et al.  Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. , 1983, Blood.

[71]  G. Knatterud,et al.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. , 1983, Blood.

[72]  A. Giles,et al.  A canine model of hemophilic (factor VIII:C deficiency) bleeding. , 1982, Blood.

[73]  H. Vinazzer.  Comparison between two concentrates with factor VIII inhibitor bypassing activity. , 1982, Thrombosis research.

[74]  C. Prowse.  Activated prothrombin complex concentrates: approaches to their preparation. , 1982, Thrombosis research.

[75]  K. Mann,et al.  The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. , 1982, Blood.

[76]  H. Kingdon,et al.  Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. , 1981, Blood.

[77]  H. V. van Houwelingen,et al.  The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.

[78]  T. Barrowcliffe,et al.  Factor VIII inhibitor bypassing activity: a suggested mechanism of action. , 1981, Thrombosis research.

[79]  S. Shapiro,et al.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. , 1980, The New England journal of medicine.

[80]  J. Griffin,et al.  Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. , 1979, The Journal of clinical investigation.

[81]  D. Feinstein,et al.  Prothrombin Complex Concentrate: Use in a Hemophiliac With a Factor VIII Inhibitor , 1977 .

[82]  C. Forbes,et al.  Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. , 1976, British medical journal.

[83]  J. Penner,et al.  Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. , 1976, JAMA.

[84]  H. Roberts,et al.  Summary Report and Recommendations of the Task Force Members and Consultants , 1975, Thrombosis and Haemostasis.

[85]  Y. Sultan,et al.  Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate. , 1974, The New England journal of medicine.

[86]  J. Penner,et al.  Activated prothrombin concentrate for patients with factor VIII inhibitors. , 1974, The New England journal of medicine.

[87]  F. Breen,et al.  Prothrombin concentrates in treatment of Christmas disease and allied disorders. , 1969, JAMA.